In leptospirosis, when are corticosteroids indicated and what is the recommended dosing regimen?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Corticosteroids in Leptospirosis: Limited Evidence, No Routine Indication

Based on the most recent and highest quality evidence, corticosteroids should NOT be routinely used in leptospirosis, as there is insufficient evidence to support their efficacy and they may increase the risk of nosocomial infections. 1

Evidence Quality and Recommendations

The 2025 Cochrane systematic review provides the most definitive guidance on this question 1. This meta-analysis of 4 randomized trials (253 participants) evaluated various corticosteroid regimens (prednisolone, hydrocortisone, dexamethasone/prednisolone combinations, or methylprednisolone) versus placebo or standard care. The evidence is very low certainty across all outcomes, meaning we cannot confidently determine whether corticosteroids help or harm patients with leptospirosis.

Key Findings from the Cochrane Review:

  • Mortality: Corticosteroids may have little to no effect (RR 1.04,95% CI 0.38-2.80) - essentially no difference
  • Serious adverse events: No clear benefit (RR 1.15,95% CI 0.32-4.11)
  • Non-serious adverse events: May increase (RR 2.00,95% CI 0.21-18.98)
  • Hospital length of stay: No clear reduction (MD 0.46 days, 95% CI -1.81 to 2.73)
  • Jarisch-Herxheimer reactions: May reduce risk (RR 0.13,95% CI 0.04-0.41), but evidence very uncertain

All included trials had methodological concerns or high risk of bias, and the confidence intervals were wide, crossing clinically important thresholds 1.

Clinical Context and Nuances

When Corticosteroids Have Been Considered:

While the evidence doesn't support routine use, some clinicians have attempted corticosteroid therapy in specific severe presentations:

  1. Severe pulmonary involvement with ARDS: Case reports suggest potential benefit when methylprednisolone (1 mg/kg/day) is given early 2, 3, but this conflicts with the systematic review finding no mortality benefit 4

  2. Severe thrombocytopenia: One trial showed prednisolone 1 mg/kg/day reduced time to platelet recovery (4.4 vs 5.7 days) and hospital stay in severe thrombocytopenia, but NOT in moderate thrombocytopenia 5

  3. Jarisch-Herxheimer reaction: High-dose methylprednisolone has been used when JHR complicates antibiotic treatment 6, though the Cochrane review questions this benefit

Critical Pitfalls:

  • The only randomized controlled trial showed corticosteroids may INCREASE nosocomial infections without improving outcomes 4
  • Most "positive" studies were case reports or poorly designed observational studies with significant methodological flaws 4
  • Timing matters: if steroids are considered, they must be given EARLY in disease course, not after established multi-organ failure
  • Standard sepsis management without corticosteroids achieves excellent outcomes - an Australian ICU series of 60 severe leptospirosis cases had 100% survival using contemporary sepsis care WITHOUT routine corticosteroids 7

Practical Management Algorithm

For all leptospirosis patients:

  • Appropriate antibiotics (ceftriaxone or penicillin) are the cornerstone
  • Conservative fluid resuscitation
  • Organ support as needed (mechanical ventilation, renal replacement therapy)
  • Standard sepsis management principles

Consider corticosteroids ONLY in:

  • Septic shock refractory to fluids and vasopressors → Use hydrocortisone 200 mg/day (per sepsis guidelines 8, 9, 10), NOT for leptospirosis specifically
  • Severe ARDS requiring mechanical ventilation → Consider methylprednisolone 1 mg/kg/day, but recognize this is based on case reports, not trials
  • Do NOT use for: mild-moderate disease, isolated thrombocytopenia, or routine severe leptospirosis

If corticosteroids are used:

  • Start ONLY after 72 hours of antibiotic therapy to reduce infection risk
  • Monitor closely for hyperglycemia and secondary infections
  • Duration should be short (5-7 days maximum)
  • Taper when vasopressors no longer needed

Bottom Line

The evidence does not support routine corticosteroid use in leptospirosis at any severity level. The 2025 Cochrane review definitively shows we cannot determine benefit, and the best-quality RCT suggests potential harm 1, 4. Excellent outcomes are achieved with standard supportive care and antibiotics alone 7. If corticosteroids are considered in life-threatening presentations, this should be based on general sepsis/ARDS principles rather than leptospirosis-specific indications, and clinicians must weigh uncertain benefits against real risks of infection and hyperglycemia.

References

Research

Corticosteroids for treatment of leptospirosis.

The Cochrane database of systematic reviews, 2025

Research

Weil's disease: rapid recovery following corticosteroid treatment: a case report.

Revista do Instituto de Medicina Tropical de Sao Paulo, 2026

Research

High dose corticosteroids in severe leptospirosis: a systematic review.

Transactions of the Royal Society of Tropical Medicine and Hygiene, 2014

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.